Mounjaro injection: what it is, how it works, and what the evidence shows

What the trial data actually showed, and why two receptors matter

The SURMOUNT-1 trial randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. At the 15 mg dose, participants lost on average around 20–21% of their starting body weight. That figure comes from the NEJM paper and is cited in NICE's technology appraisal TA1026, published in December 2024. The difference from earlier GLP-1 injections comes down to receptor biology. Tirzepatide binds both GLP-1 and GIP receptors, two hormones released after eating that signal fullness, slow gastric emptying, and influence how the body handles glucose. Most injections in this class act only on GLP-1. Activating both pathways appears to produce a stronger and more sustained appetite-suppression effect. Worth being clear, though: the headline trial numbers reflect people who stayed on the highest tolerated dose for the full study period, alongside a reduced-calorie diet and increased activity. Individual results vary, and a prescriber will discuss realistic expectations with you before treatment starts.

How the Mounjaro injection is given, and what the KwikPen actually involves

A question our prescribers hear most weeks is whether the injection itself is difficult or painful. The short answer is that most people find it far less daunting than they expected. The Mounjaro KwikPen is a pre-filled, dial-free device with a small, fine needle; you press it against the skin of your abdomen, thigh, or upper arm and hold it in place for a few seconds. The pen contains four doses, one per week. You rotate injection sites to avoid skin irritation. Before injecting, cleaning the site with an alcohol swab is standard practice. Storage is in the fridge at 2–8°C; if you need to travel, the SmPC sets out the exact room-temperature window, always check the Patient Information Leaflet or the Mounjaro SmPC on the eMC for the current figures rather than relying on a summary. Disposal of used pens requires a sharps container, not the household bin. If you are planning to take your treatment abroad, the logistics are worth thinking through in advance, there is specific guidance on travelling internationally with Mounjaro worth reading before you fly.

Who the Mounjaro injection is licensed for in the UK

The UK licence covers two populations: adults managing their weight, and adults with type 2 diabetes. For weight management, the SmPC threshold is a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or prediabetes. NICE's TA1026 sets a higher NHS bar (BMI of 35 or above with at least one qualifying comorbidity) though thresholds are 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. BMI alone is not the whole picture; the prescriber reviews your full medical history, current medications, and any contraindications before approving treatment. Tirzepatide is not recommended during pregnancy, breastfeeding, or when trying to conceive, and it is not licensed for under-18s. If you want to understand all the conditions tirzepatide is used for, the licensed indications page covers that in more detail. For context on what the injection costs privately, the Eli Lilly price change that took effect in September 2025 is worth knowing about before you compare providers.

Common side effects to know before you start

Most side effects are gastrointestinal and most are temporary. Nausea is the most commonly reported, followed by loose stools, constipation, indigestion, and burping. These tend to be most noticeable in the first week or two after a dose increase, then settle. Starting at 2.5 mg is specifically designed to reduce this burden before the prescriber steps the dose up. Fatigue, headache, and mild injection-site reactions are also reported. More serious but less common concerns include acute pancreatitis; in January 2026 the MHRA issued a Drug Safety Update flagging severe, persistent stomach pain (especially pain that radiates to the back) as a reason to seek urgent medical attention. You can report any suspected side effect through the Yellow Card scheme. For a fuller picture of what eating well on treatment looks like, including why protein and hydration matter when appetite drops significantly, the nutrition guidance for people on Mounjaro is a practical read. If you have specific questions about how the Mounjaro injection works in practice, our FAQs cover the most common ones. When you are ready to explore whether treatment is clinically suitable for you, start your free consultation with our prescribers.